This list is for the codes only. Use this list to give to the IT programmers. The long version has additional explanations and notes for many of the codes.

These tables are also available in a printable version (PDF, 533 KB).

Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2010)

ICD-9-CM Code^ Explanation of Code
140.0 – 209.36 Malignant Neoplasms
209.70 – 209.79 Secondary neuroendocrine tumors
225.0 – 225.9 Benign neoplasm of brain and spinal cord neoplasm
227.3 – 227.4 Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland
227.9 Benign neoplasm; endocrine gland, site unspecified
228.02 Hemangioma; of intracranial structures
228.1 Lymphangioma, any site
230.0 – 234.9 Carcinoma in situ
236.0 Endometrial stroma, low grade
237.0 – 237.9 Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system
238.4 Polycythemia vera
238.6 – 238.79 Other lymphatic and hematopoietic tissues  
239.6 – 239.89 Neoplasms of unspecified nature
273.2 Other paraproteinemias
273.3 Macroglobulinemia
288.3 Eosinophilia
288.4 Hemophagocytic syndromes
795.06 Papanicolaou smear of cervix with cytologic evidence of malignancy
795.16 Papanicolaou smear of vagina with cytologic evidence of malignancy
796.76 Papanicolaou smear of anus with cytologic evidence of malignancy
V10.0 – V10.91 Personal history of malignancy
V12.41 Personal history of benign neoplasm of the brain

The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.

Supplementary List #1-ICD-9-CM Codes that Should Be Followed by or Associated with a Neoplasm Code

ICD-9-CM Code^ Explanation of Code
258.02 – 258.03 Multiple endocrine neoplasia (MEN) type IIA and IIB
285.22 Anemia in neoplastic disease
289.83 Myelofibrosis (NOS) (9961/3)
338.3 Neoplasm related pain (acute, chronic); Cancer associated pain
511.81 Malignant pleural effusion (code first malignant neoplasm if known).
789.51 Malignant ascites (code first malignant neoplasm if known).

NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm.

Supplementary List #2-ICD-9-CM Code List to Screen for Cancer Cases Not Identified by Other Codes (Effective Date: 1/1/2010)

ICD-9-CM Code^ Explanation of Code
042 Acquired Immunodeficiency Syndrome (AIDS)
079.4 Human papillomavirus
079.50 – 079.59 Retrovirus (HTLV, types I, II and 2)
209.40 – 209.69 Benign carcinoid tumors
210.0 – 229.9 Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 227.9, 228.02, and 228.1, which are listed in the Reportable list)
235.0 – 236.6, 238.0-239.9 Neoplasms of uncertain behavior (except for 236.0, 238.4, 238.6, 238.71-238.79, 239.6, 239.7, 239.81 and 239.89, which are listed in the Reportable list)
253.6 Syndrome of inappropriate secretion of antidiuretic hormone
259.2, 259.8 Other Endocrine disoders
273.0 – 273.1, 273.9 Disorders of plasma protein metabolism
275.42 Hypercalcemia
277.88 Tumor lysis syndrome following antineoplastic drug therapy
279.00, 279.02 – 279.06 Disorders involving the immune mechanism
279.10, 279.12-279.13 Deficiency of cell-mediated immunity
279.2 – 279.9 Combined immunity deficiency
284.81 – 284.9 Other and unspecified aplastic anemias
285.0, 285.3 Other and unspecified anemias
288.03 Drug induced neutropenia
289.89 Other specified diseases of blood and blood-forming organs
323.81 Encephalomyelitis; specified cause NEC
379.59 Opsoclonia
528.01 Mucositis due to antineoplastic therapy
630 Hydatidiform Mole
686.01 Pyoderma gangrenosum
695.89 Sweet’s syndrome
701.2 Acanthosis nigricans
710.3 – 710.4 Diseases of connective tissue
785.6 Enlargement of lymph nodes
790.93 Elevated prostate specific antigen [PSA]
795.8 Abnormal tumor markers; Elevated tumor associated antigens [TAA];‎ Elevated tumor specific antigens [TSA];‎ Excludes: Elevated prostate specific antigen [PSA] (790.93)‎
795.81 – 795.89 Abnormal tumor markers
999.31 Infection due to central venous catheter (porta-cath)
999.81 Extravasation of vesicant chemotherapy
E879.2 Adverse effect of radiation therapy
E930.7 Adverse effect of antineoplastic therapy
E933.1 Adverse effect of immunosuppressive drugs
V07.31, V07.39 Other prophylactic chemotherapy
V07.8 Other specified prophylactic measure
V12.72 History of colonic polyps
V15.3 Irradiation: previous exposure to therapeutic or ionizing radiation
V42.81 – V42.82 Organ or tissue replaced by transplant, Bone marrow transplant
V51.0 Encounter for breast reconstruction following mastectomy
V52.4 Breast prosthesis and implant
V54.2 Aftercare for healing pathologic fracture
V58.0 – V58.12 Encounter for radiation  and chemotherapy
V58.42 Aftercare following surgery for neoplasm
V66.1 – V66.2 Convalescence following radiotherapy and/or chemotherapy
V67.1 – V67.2 Radiation and chemotherapy follow up
V71.1 Observation for suspected malignant neoplasm
V76.0 – V76.9 Special screening for malignant neoplasm
V78.0 – V78.9 Special screening for disorders of blood and blood-forming organs
V82.71 Screening for genetic disease carrier status
V82.79 Other genetic screening
V82.89 Genetic screening for other specified conditions
V82.9 Genetic screening for unspecified condition
V84.01 – V84.09 Genetic susceptibility to malignant neoplasm
V84.81 Genetic susceptibility to multiple endocrine neoplasia [MEN]
V86.0 – V86.1 Estrogen receptor status
V87.41 Personal history of antineoplastic chemotherapy

^ International Classification of Diseases, Ninth Revision, Clinical Modification, 2009.